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Theobjective ofthisstudywastodetermine theeﬀects ofvitaminD3 pluscalciumsupplements(D3-calcium)onpharmacokinetics
of isoﬂavones in Thai postmenopausal women. This study was an open-labeled, randomized three-phase crossover study. Twelve
healthy subjects were randomized to receive one of the following regimens: (a) a single dose of isoﬂavones, (b) a single dose of
isoﬂavones,and D3-calcium, or (c) continuous D3-calcium for 7 days followed by a single dose of isoﬂavonesonthe 8th day. After
a washout period, subjects were switched to receive the 2 remaining regimens according to their randomized sequences. Blood
samples were collected before dose and at speciﬁc time points until 32 hours after isoﬂavone administration. Plasma was treated
withβ-glucuronidase/sulfatasetohydrolyze glucuronide andsulfateconjugatesofdaidzeinandgenistein.Plasmaconcentrationsof
daidzein and genistein were determined by high performance liquid chromatography. The estimated pharmacokinetic parameters
of isoﬂavones were time to maximal plasma concentration (Tmax), maximal plasma concentration (Cmax), half-life (t1/2)a n da r e a
under the plasma concentration-time curve (AUC). Tmax of daidzein and genistein after regimen B was signiﬁcantly longer than
that of regimen A. Other pharmacokinetic parameters of daidzein and genistein obtained following the three regimens were not
signiﬁcantlydiﬀerent.
1.Introduction
Menopause is the permanent cessation of menstruation
and ovarian function characterized by a lack of estro-
gen production [1]. Acute estrogen deﬁciency may cause
menopausal symptoms that include a variety of symptoms,
such as vasomotor instability (hot ﬂashes and night sweats),
insomnia, palpitations, anxiety, urinary symptoms and
urethral syndrome, vaginal dryness, dyspareunia, and loss
of libido, whereas chronic estrogen deﬁciency may result
in osteoporosis, strokes, and cardiovascular diseases [2].
Estrogen therapy is highly eﬀective for relieving menopausal
symptoms and for preventing osteoporosis [3]. Nonethe-
less, the use of estrogen increases the risk of endome-
trial cancer [4], whereas this adverse incidence could be
avoided by using continuous combined estrogen-progestin
replacement therapy [5]. However, recent evidence from
the Women’s Health Initiative (WHI) clinical trial suggests
that estrogen plus progestin initially increases the risk of
coronary heart disease, stroke, and venous thromboem-
bolism [6].
The concern over the potential adverse eﬀects of hor-
monal replacement therapy (HRT) leads many women to
look for other alternatives. One modality that has been
widely investigated is soy supplement. Soy foods contain
isoﬂavones that are structurally similar to estrogen but have
weaker hormonal eﬀects: binding weakly to the estrogen
receptor α of the uterus, ovaries, and breast, but more
strongly to the estrogen receptor β that is found in the
bone [7]. Soybean protein and foods containing soy are an
integral part of many Asian diets and contain signiﬁcant
amounts of isoﬂavones either as the unconjugated aglycones,
such as daidzein and genistein, or as diﬀerent types of their
respective glycoside conjugates, such as daidzin and genistin
[7].Isoﬂavoneshavereceived considerableattentionfor their
potential role in the alleviation of hot ﬂushes [8]a sw e l la s
reducing the risk of osteoporosis [9, 10] in postmenopausal
women.2 Evidence-Based Complementary and Alternative Medicine
Generally, adequate supplementation of calcium and
vitamin D is recommended as a cornerstone for the
prevention and treatment of osteoporosis [11]. A daily
intake of at least 1,200mg of calcium is recommended for
all women with osteoporosis [12]. In addition, there is
compelling scientiﬁc evidence that oral vitamin D reduces
the risk of hip and any nonvertebral fractures in ambulatory
or institutionalized elderly persons [13]. Nonetheless, oral
vitamin D appears to reduce the risk of hip fractures only
when calcium supplementation is added [14].
Thus, it is possible that both peri- and postmenopausal
women might consider using the combination of vitamin
D, calcium, and soy isoﬂavones for the prevention and
treatment of postmenopausal osteoporosis instead of HRT.
Nonetheless,thepharmacokineticinteractionsbetweenthese
agents have not been reported as of yet. Thus, the purpose
of this study was to determine the eﬀects of vitamin D plus
calcium supplements on pharmacokinetics of isoﬂavones in
Thai postmenopausal women.
2.Materialsand Methods
2.1. Study Design. This study was a randomized, open-
labeled, crossover-three phase study, with washout periods
of at least 2 weeks. The study was approved by the Human
Research Ethics Committee of the Faculty of Medicine,
Chiang Mai University, and complied with the Helsinki
Declaration.
2.2. Subjects. A total of 12 postmenopausal women aging
≥45 years exhibiting serum follicle-stimulating hormone
concentration>20IU/Lwereenrolledinthisstudy.Allhadto
be in good general health on the basis of medical history and
a thorough physical examination. Routine blood examina-
tions including complete blood count, blood urea nitrogen,
serum creatinine, and liver function test were carried out
to exclude subjects with abnormal hematological diseases or
impaired kidney and liver function. Blood concentrations
of calcium and phosphate had to be within normal ranges
of 8.5–10.5 and 2.5–5.0mg/dL, respectively. The body mass
index of all subjects had to be within 18–25kg/m2.T h e
subjects were advised to maintain their usual diet and to
avoid consuming high quantities of vitamin D or a high cal-
cium diet as well as to avoid soy food throughout the study.
Supplements of vitamin D, calcium, and isoﬂavones were
not allowed throughout the study. Exclusion criteria were
subjects with known premenopausal status (<12 months
since the last spontaneous menstrual bleeding), history of
chronic renal, liver, pulmonary, or cardiovascular diseases,
recent cigarette smoking, substance abuse or addiction, use
of antibiotics within the previous 6 weeks, consumption
of >2 alcoholic drinks/day, regular use (>1 dose/week) of
over-the-counter or prescription medications, as well as
a history of malignancy, hyperparathyroidism, or breast
disease.
2.3. Isoﬂavones and Vitamin D3 plus Calcium (D3-Calcium)
Supplements. The isoﬂavone preparation used in this study
was the commercial soy isoﬂavone capsule, Flava soy (1 cap-
sule contains not less than 25mg isoﬂavones, manufactured
by Thai Herbal Products Co., Ltd, Thailand). D3-calcium
supplement was the commercial Caltrate 600 + D (1 tablet
contains vitamin D3 200IU plus calcium 600mg, manufac-
tured by Wyeth-Ayerst Co., Ltd, Thailand).
2.4. Dosage and Drug Administration. Subjects were admit-
ted to the Clinical Pharmacology Unit, Faculty of Medicine,
Chiang Mai University at 6:30AM after an overnight fast of
at least 8h. Subjects were randomized to receive (a) a single
dose of 2 capsules of Flava soy (single ISO), (b) a single
dose of 2 capsules of Flava soy and 1 tablet of Caltrate
600 + D (“single ISO + D3-calcium”), or (c) 1 tablet of
Caltrate 600 + D twice a day after breakfast and dinner for
7 days, followed by 2 capsules of Flava soy on the 8th day
(continuous D3-calcium/single ISO). Subjects were asked
to remain upright and asked to fast for 2 hours (h) after
isoﬂavone administration. Water and lunch were served at
2h and 6h after dosing, respectively. Blood samples were
collected at speciﬁc time points (see below). After blood
sample collection at 12h afterdose, subjects were discharged
and were asked to come back again on the next day for
blood sample collections at 24h and 32h afterdose. After a
washout period of at least 2 weeks, subjects were switched
to receive the two remaining regimens according to their
randomized sequences. Subjects were required to refrain
from drinking caﬀeine and alcohol containing beverages in
order to standardize experimental conditions.
2.5. Blood Sample Collection. Venous blood samples (10mL/
each) for the determination of soy isoﬂavones were collected
beforedose and then at 1, 2, 4, 6, 8, 10, 12, 24, 32h after
isoﬂavone administration. Samples were obtained from the
forearm by venipuncture through an indwelling intravenous
catheter (BD Insyte) and collected in heparinized vacutainer
(BD Insyte). The blood collecting tubes were centrifuged at
2,500rpm for 10min, and the plasma was separated and
frozen at −80◦C until analysis.
2.6. Determination of Isoﬂavone Concentrations
2.6.1. High-Performance Liquid Chromatography (HPLC)
Condition. The assay of isoﬂavone content was modiﬁed
from the HPLC method and conditions previously described
by Thomas et al. [15]. Chromatographic separation was
performed on 5μm C18, 100×4.6 i.d. analytical and guard
columns. The chromatography condition consisted of 2
mobilephases. MobilephaseAwas250:105:105(v/v/v)and
Mobile phase B was 250:200:250 (v/v/v) of 40mM ammo-
nium acetate/acetonitrile/methanol, respectively. Twenty μL
of perchloric acid and 250μL of 1.44mM sodium dodecyl
sulfate were added into both mobile phases. The HPLC
system was run by 100% mobile phase A for 2.50min
and followed by 100% mobile phase B for 11.50min. The
ﬂow rate was maintained at 1mL/min, the column was
maintained at 25◦C, and the analytes were detected by UV
absorption at 259nm.Evidence-Based Complementary and Alternative Medicine 3
2.6.2. Sample Preparation. Initially, the mixture of β-glucu-
ronidase/sulfatase enzyme was made up freshly by adding
500μLo fβ-glucuronidase/sulfatase from Helix pomatia
(SigmaG-0876) into10mL of0.1M sodiumacetatecontain-
ing 0.1g ascorbic acid and 0.01g ethylenediaminetetraacetic
acid (EDTA). Aliquot of 125μL of plasma was transferred to
a 1.5mL plastic vial and treated with 0.25mL of a mixture
of β-glucuronidase/sulfatase to hydrolyze glucuronide and
sulfate conjugates of daidzein and genistein. The tubes were
capped and heated overnight in water bath (37◦C, 15–18h),
then removed from the bath, and allowed to cool at room
temperature.
2.6.3. Determination of Isoﬂavone Concentrations in Plasma.
The assay was modiﬁed from protein precipitation pro-
cedure. Brieﬂy, after enzymatic hydrolysis, plasma sam-
ples were spiked with 10μL of internal standard (IS,
50,000ng/mL ﬂuoresceinin80% methanol) and thendepro-
teinated by mixing plasma samples with 500μLa c e t o n i t r i l e ,
vortex mixing for 30sec and centrifuged at 14,000rpm
for 10min, respectively. An aliquot of the supernatant
was removed and evaporated for 2h at 60◦C. The residue
was dissolved in 50μL of the mobile phase, and 5μLo f
the sample was injected onto the HPLC system. Chro-
matogram of plasma containing daidzein, genistein, and
IS is presented in Figure 1. The isoﬂavone contents of
samples were determined by using a calibration curve of
peak height ratios of isoﬂavones (daidzein and genistein)
and IS versus respective isoﬂavone concentrations (37.5, 75,
150, 300, 600, 1200, and 2400ng/mL) with the use of linear
regression. The linear regression analysis of peak height
ratios of isoﬂavones versus isoﬂavone concentrations con-
sistently yielded coeﬃcients of determinant (r2) of 0.997 or
better.
Intraday and interday precisions were determined using
3 quality control samples of daidzein and genistein in
plasma (112.5, 1100, and 2200ng/mL). For determination
of daidzein concentrations in plasma, the mean percentages
of coeﬃcient of variation (%CV) of intraday and interday
precision were 4.10% and 6.86%, respectively, whereas the
mean deviation of intraday and interday assay were 4.27%
and −0.41%, respectively. The mean recovery of daidzein
from the determination procedure was 89.63%. Fordetermi-
nation ofgenistein concentrationsin plasma, the mean %CV
of intraday and interday precision was 4.36% and 5.48%,
respectively, whereas the mean deviation of intraday and
interdayassay was10.37%and7.37%,respectively.Themean
recovery of genistein from the determination procedure was
88.58%.
2.7. Data Analysis and Statistical Methods
2.7.1. Pharmacokinetic Parameters. Time to reach peak con-
centration (Tmax, h) and maximal plasma concentration
(Cmax,ng/mL) was obtained directly by visual inspection of
each subject’s plasma concentration-time proﬁle. The slope
of the terminal log-linear portion of the concentration-time
proﬁle was determined by least-squares regression analysis
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Figure 1: Chromatogram of plasma sample containing 2,400ng/
mL of daidzein (retention time, k = 9.980min) and genistein (k =
12.541 minutes) and 4,000ng/mL of ﬂuorescein (internal standard,
k = 6.425 minutes).
and was usedas the elimination rate constant(Ke).The elim-
ination half-life (t1/2) was calculated as 0.693/Ke.T h eA U C
from time zero to the last quantiﬁable point (AUC0−32)
was calculated using the trapezoidal rule. Extrapolated
A U Cf r o mt h el a s tq u a n t i ﬁ a b l et i m et oi n ﬁ n i t y( A U C 32−∞)
was determined as Ct/Ke.T o t a lA U C 0−∞ was the sum of
AUC0−32+A U C 32−∞. The calculation was performed using
the TopFit software version 2.0 for PC.
2.7.2. Statistical Analysis. The pharmacokinetic parameters
were presented as mean ± standard deviation (SD). The
mean values of pharmacokinetic parameters obtained from
regimen A (single ISO) were compared to those of the two
remaining regimens using Wilcoxon signed-rank test.
3.Results
The demographic characteristics of 12 subjects enrolled in
the studyare shown inTable 1. Allcompletedstudy protocol;
however data from one subject was excluded from analysis
since isoﬂavones were detected in her serum at baseline of
“single ISO + D3-calcium” phase. Every subject was healthy
o nt h eb a s i so fm e d i c a lh i s t o r y ,a sw e l la sp h y s i c a la n d
biochemical investigations.
The mean plasma concentration-time curves after taking
three diﬀerent regimens of soy extract are shown in Figures
2 and 3. The plasma concentration-time proﬁles of daidzein
and genistein were typically biphasic regardless of soy extract
regimens taken. The ﬁrst and second peak concentrations
of both aglycones were generally attained at 2–4h and
6–8h, respectively. The mean values of pharmacokinetic
parameters of daidzein and genistein after receiving three
diﬀerent regimens are shown in Tables 2 and 3.
Ofallpharmacokineticparameters, onlyTmax ofdaidzein
and genistein after “single ISO + D3-calcium” was signif-
icantly longer than “single ISO” (Tables 2 and 3). Other
pharmacokinetic parameters (Cmax,A U C 0−32,A U C 0−∞,a n d
t1/2) of daidzein and genistein analyzed after the three
diﬀerent regimens were not signiﬁcantly diﬀerent.4 Evidence-Based Complementary and Alternative Medicine
Table 1: The demographic characteristics of subjects enrolled in the study (n = 12).
Subject Age Weight Height BMI FSH
No. (y) (kg) (m) (kg/m2)( I U / L )
1 52 57.00 1.60 22.27 49.20
2 53 52.50 1.53 22.43 48.50
3 54 54.00 1.51 23.68 33.50
4 54 60.00 1.56 24.65 49.40
5 56 48.50 1.45 23.07 38.60
6 56 42.00 1.44 20.25 68.50
7 49 58.50 1.66 21.23 128.20
8 55 58.00 1.53 24.78 68.80
9∗ 57 48.50 1.50 21.56 101.00
10 62 60.50 1.60 23.63 53.33
11 59 49.00 1.51 21.50 40.79
12 62 48.00 1.42 23.81 63.49
Mean 55.75 53.04 1.53 22.74 61.94
SD 3.70 5.63 0.07 1.37 26.43
∗Data from subject no. 9 was ruled out because isoﬂavone concentration was detected in plasma sample at baseline of “single ISO + D3-calcium” phase.
Table 2: Pharmacokinetic parameters of daidzein after receiving three diﬀerent regimens.
Pharmacokineticparameters† Treatment regimens
Single ISO Single ISO +D3-calcium‡ Continuous D3-calcium/single ISO
Tmax (h) 5.50 8.00∗ 6.08
(2.11) (1.79) (2.50)
Cmax (ng/mL) 506.09 396.32 488.05
(299.62) (115.37) (165.90)
t1/2 (h) 6.80 6.34 6.26
(2.98) (5.29) (3.73)
AUC0−32 (ng·h/mL) 3474.05 2968.71 4620.55
(931.53) (627.60) (2148.09)
AUC0−∞(ng·h/mL) 4905.23 4938.40 5961.22
(1150.99) (1611.00) (2546.45)
Data represents mean (SD). †The parameters were derived from analysis of the individual concentration-time curve. ‡Data from one subject was ruled out
because isoﬂavone concentration was detected in plasma sample at baseline. Single ISO: a single dose of Flava soy; Single ISO + D3-calcium:as i n g l ed o s eo f
Flava soy and Caltrate 600 + D; Continuous D3-calcium/single ISO: 1 tablet of Caltrate 600 + D twice a day for 7 days, followed by a single dose of Flava soy
on the 8th day. ∗P<. 05versus Single ISO.
Table 3: Pharmacokinetic parameters of genistein after receiving three diﬀerent regimens.
Pharmacokineticparameters† Treatment regimens
Single ISO Single ISO +D3-calcium‡ Continuous D3-calcium/single ISO
Tmax (h) 4.58 7.64∗ 6.08
(2.11) (2.16) (2.78)
Cmax (ng/mL) 593.33 578.99 688.56
(303.31) (240.98) (285.42)
t1/2 (h) 8.31 7.44 8.86
(4.90) (2.27) (4.09)
AUC0−32 (ng·h/mL) 5804.19 6574.74 7758.56
(2643.87) (2625.30) (5068.69)
AUC0−∞ (ng·h/mL) 6787.62 7434.65 9091.58
(2793.66) (2748.42) (5394.67)
Data represents mean (SD). †The parameters were derived from analysis of the individual concentration-time curve. ‡Data from one subject was ruled out
because isoﬂavone concentration was detected in plasma sample at baseline. Single ISO: a single dose of Flava soy; Single ISO + D3-calcium:as i n g l ed o s eo f
Flava soy and Caltrate 600 + D; Continuous D3-calcium/single ISO: 1 tablet of Caltrate 600 + D twice a day for 7 days, followed by a single dose of Flava soy
on the 8th day. ∗P<. 05versus Single ISO.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Mean plasma daidzein concentration-time curves after
receiving three diﬀerent regimens obtained from subjects who
completed the study without protocol deviation (n = 11). Each
point on the curves represents mean plasma concentration at
the corresponding time point. Single ISO: a single dose of Flava
soy; Single ISO + D3-calcium: a single dose of Flava soy and
Caltrate 600 + D; Continuous D3-calcium/single ISO:1t a b l e to f
Caltrate 600 + D twice a day for 7 days, followed by a single dose
of Flava soy on the 8th day.
4.Discussion
This is the ﬁrst study to investigate the interaction between
vitamin D and calcium with soy isoﬂavones. Since the study
design of this study was similar to that of the bioequivalence
testing, 12 subjects were enrolled in this study according to
theminimum number ofsubjectsstipulatedby theCanadian
and European guidelines for bioequivalence testing.
Theoretically, the isoﬂavones in nonfermented soy food
appear mostly as the glycoside conjugates, whereas the
aglycones (e.g., daidzein, genistein, etc.) dominate in fer-
mented soy products [16]. Since the amounts of daidzein
and genistein detected in the Flava Soy capsule were
negligible (data not shown), it was postulated that the
predominant forms of isoﬂavones existing in the prepara-
tion were glycoside conjugates. However, because human
intestinal or gut microﬂoral glucosidases seemingly cleave
these moieties before these isoﬂavones can be absorbed,
most of the absorbed isoﬂavones are aglycones [7]. The
absorbed aglycones are then largely converted to their β-
glucuronides by enzymes in the gut wall, which may be a
major site of glucuronidation, and also in the liver after
they reach systemic circulation. In fact, isoﬂavones are
predominantly conjugated with glucuronic acid and, to a
lesser extent, with sulfate [17]. The purpose of using a
mixture of β-glucuronidase/sulfatase in the quantiﬁcation
of plasma isoﬂavone concentrations in this study was to
hydrolyze glucuronide and sulfate conjugates to aglycones.
Thus, plasma concentrations of daidzein and genistein
were determined rather than their glucuronide and sulfate
conjugates.
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Figure 3: Mean plasma genistein concentration-time curves after
receiving three diﬀerent regimens obtained from subjects who
completed the study without protocol deviation (n = 11). Each
point on the curves represents mean plasma concentration at the
corresponding time point. Single ISO: a single dose of Flava soy;
Single ISO + D3-calcium: a single dose Flava soy and Caltrate 600 +
D; Continuous D3-calcium/single ISO: 1 tablet of Caltrate 600 + D
twice a day for 7 days, followed by a single dose of Flava soy on the
8th day.
In this study, the biphasic pattern observed from the
concentration-time curve of both aglycones indicates an
enterohepatic recirculation as already suggested by several
authors [18–20]. The ﬁrst peak corresponds to absorption
occurring readily in the small intestine [18, 19, 21]w h e r et h e
glycoside forms of isoﬂavones are hydrolyzed by glucosidases
t ot h ea g l y c o n ef o r m s[ 22]. The second peak possibly results
from the entero-hepatic recirculation of the glucuronide
and sulfate conjugates of isoﬂavones excreted in the bile
[19]. In this study, the second peak concentrations of both
isoﬂavones were attained approximately at 2h after lunch
in most subjects; this ﬁnding supports the existence of
entero-hepatic recirculation. Additionally, the long transit
time of unabsorbed glycosides reaching the colon and
subsequently cleaved by microﬂoral glucosidases may also
help to explain the second surge of plasma daidzein and
genistein concentrations [23].
The mean Tmax ofdaidzein (5.50 + 2.11h) and genistein
(4.58 + 2.11h) was quite shorter than those of approxi-
mately 8-9h afteringestion ofisoﬂavone conjugatesreported
in Caucasian subjects [18, 20]. This discrepancy might be
the result from such factors as race, uptake rates, and
rapidity ofhydrolysis of glycosidesby gut bacteria or gutwall
enzymes. However, the diﬀerence in the rate of cleavage of
these glycosides by gut wall enzymes and bacteria among
the diﬀerent populations seems to be a more plausible
explanation since the Tmax of these aglycones of the present
study was more comparable to another study done in the
Asian population [19, 24].
“Single ISO + D3-calcium” signiﬁcantly delayed Tmax
of both daidzein and genistein compared to “single ISO.”6 Evidence-Based Complementary and Alternative Medicine
The reason behind the delay in Tmax by D3-calcium is
unknown. Since aglycones are absorbed by passive diﬀusion
[25], and there is no evidence for facilitated or active trans-
port of isoﬂavones, it seems unlikely that D3-calcium exerts
thisinterferenceviatheinvolvementofacarrierorsaturation
process. However, this delayed rate of absorption might be
the result from at least 3 possibilities: ﬁrstly, since it has been
shown that the rate-limiting step for absorption is initial
hydrolysis of sugar moiety [26], therefore, either vitamin
D or calcium (or both) possibly and transiently inhibits
glucosidase activity leading to the delayed cleavage of these
glycoside conjugates into aglycones and thus increases in
their Tmax. Secondly, calcium carbonate in Caltrate 600 + D
may cause delayed gastric emptying time leading to the
delayed Tmax [27]. Thirdly, some inactive ingredients in
Caltrate 600 + D might alter the bioavailability of aglycones
because it has been shown that ﬁber and carbohydrates are
associated with diﬀerences in the absorption of aglycones
[28]. Among these possibilities, the latter appears unlikely
becausetheamountofinactiveingredientswouldbetoolittle
to cause such a signiﬁcant delay.
Although“singleISO+D3-calcium”signiﬁcantlydelayed
the Tmax of both isoﬂavones, single dose and multiple doses
of D3-calcium did not signiﬁcantly aﬀect other pharmacoki-
netic characteristics of daidzein and genistein since Cmax,
AUC, and t1/2 of these isoﬂavones were not signiﬁcantly
diﬀerent among the three regimens. Therefore, D3-calcium
only delayed the absorption of isoﬂavones without signif-
icant eﬀects on the extent of isoﬂavones absorbed or on
their metabolism. However, we postulate that these drug
interactions cause a negligible eﬀect on isoﬂavones’ ther-
apeutic outcomes because reduced absorption rate is only
important if a rapid pharmacological eﬀect is sought which
depends on attaining a high peak concentration (e.g., with
antibiotics and analgesics) [29]. Therefore, coadministration
ofD3-calciumandisoﬂavonesseemstobethesimplemethod
toenhance drugcompliance,especially intheelderlypatients
taking several medications, and this advantage might out-
weigh the minor eﬀect of D3-calcium on pharmacokinetics
of isoﬂavones. Indeed, the D3-calcium-isoﬂavones should
be encouraged for the treatment of some indications (such
as postmenopausal osteoporosis) and might become an
appropriate alternative food supplementation to HRT in
postmenopausal women in the near future. Nevertheless, the
clinical studies in this aspect should be further investigated.
The major limitation of this study was the lack of quan-
tiﬁcation of isoﬂavone conjugates (daidzin and genistin)
in the soy preparation used; the variations in amount per
capsule may contribute to the remarkably high variations in
Cmax and AUC of aglycones among the diﬀerent regimens,
even in the same subjects. In addition, lack of veriﬁca-
tion of dissolution of the soy formulation was another
limitation, yielding the unanswered question of whether
delayed absorption of aglycones was due to the diﬀerent
dissolution rate or drug interaction. The small sample
size also contributes to a marked variation encountered in
this study. Future studies should be designed to overcome
these limitations by determination of isoﬂavone contents
existing in the study preparation, as well as their dissolution
proﬁles, and by using a larger sample size. Besides, although
the washout period of at least 2 weeks assigned in this
study might be suﬃciently long comparing to plasma t1/2
of vitamin D (191–25h) and isoﬂavones, it seems to be
rather short comparing to tissue t1/2 of vitamin D stored
in fat depots. This might provide potential carryover eﬀects
of the vitamin D intervention on the subsequent study
phases. Finally, since serum D3 production is inﬂuenced
by an exposure to sunlight, lack of assessment and control
of sunlight exposure in the individual subject should be
considered as another limitation.
5.Conclusion
Simultaneous administration of D3-calcium delayed Tmax of
daidzein and genistein without signiﬁcant alteration in Cmax,
AUC0−32,A U C 0−∞,a n dt 1/2 of both aglycones.
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